BLUE insider transaction filings
bluebird bio, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-06-03. Screen BLUE transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for BLUE between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — bluebird bio, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-06-03 | 4 | Vittiglio Joseph — Chief Business & Legal Officer | Code (U): 1,143 · Disposition to issuer (D): 3,125 · Grant/award (A): 2,500 · Disposition to issuer (D): 2,500 | EDGAR |
| 2025-06-03 | 4 | Agwunobi John O — Director | Code (U): 1,323 · Disposition to issuer (D): 1,245 | EDGAR |
| 2025-06-03 | 4 | Vachon Mark — Director | Code (U): 1,252 · Disposition to issuer (D): 1,245 | EDGAR |
| 2025-06-03 | 4 | Colvin Richard A — Chief Medical Officer | Code (U): 3,552 · Disposition to issuer (D): 4,166 · Grant/award (A): 2,500 · Disposition to issuer (D): 2,500 | EDGAR |
| 2025-06-03 | 4 | Tita-Reid Najoh — Director | Code (U): 1,163 · Disposition to issuer (D): 1,245 | EDGAR |
| 2025-06-03 | 4 | Obenshain Andrew — President and CEO, Director | Code (U): 9,027 · Disposition to issuer (D): 9,300 · Grant/award (A): 14,820 · Disposition to issuer (D): 14,820 | EDGAR |
| 2025-06-03 | 4 | Leiderman Elisabeth — Director | Code (U): 1,112 · Disposition to issuer (D): 1,245 | EDGAR |
| 2025-06-03 | 4 | Jones-Burton Charlotte — Director | Code (U): 928 · Disposition to issuer (D): 1,245 | EDGAR |
| 2025-06-03 | 4 | Klima Thomas J — See Remarks | Code (U): 3,414 · Disposition to issuer (D): 4,464 · Grant/award (A): 2,500 · Disposition to issuer (D): 2,500 | EDGAR |
| 2025-06-03 | 4 | Sterling O. James — Chief Financial Officer | Disposition to issuer (D): 5,000 · Grant/award (A): 2,500 · Disposition to issuer (D): 2,500 | EDGAR |
| 2025-06-03 | 4 | Leschly Nick — Director | Code (U): 14,416 · Code (U): 2,284 · Code (U): 6,150 · Disposition to issuer (D): 1,245 | EDGAR |
| 2025-06-03 | 4 | Paulson Richard A. — Director | Code (U): 155 · Disposition to issuer (D): 1,323 | EDGAR |
| 2025-06-03 | 4 | Cloonan Michael — Director | Disposition to issuer (D): 1,867 | EDGAR |
| 2025-03-05 | 4 | Colvin Richard A — Chief Medical Officer | Sale (S): 584 @ $3.92 | EDGAR |
| 2025-03-05 | 4 | Klima Thomas J — See Remarks | Sale (S): 500 @ $3.92 | EDGAR |
| 2025-03-05 | 4 | Obenshain Andrew — President and CEO, Director | Sale (S): 921 @ $3.92 | EDGAR |
| 2025-02-12 | 4 | Obenshain Andrew — President and CEO, Director | Grant/award (A): 763 @ $0 | EDGAR |
| 2025-02-05 | 4 | Klima Thomas J — See Remarks | Sale (S): 122 @ $7.39 | EDGAR |
| 2025-02-05 | 4 | Colvin Richard A — Chief Medical Officer | Sale (S): 64 @ $7.39 | EDGAR |
| 2025-02-05 | 4 | Vittiglio Joseph — Chief Business & Legal Officer | Sale (S): 238 @ $7.39 | EDGAR |
| 2025-02-05 | 4 | Obenshain Andrew — President and CEO, Director | Sale (S): 86 @ $7.39 | EDGAR |
| 2025-01-08 | 4 | Colvin Richard A — Chief Medical Officer | Sale (S): 19 @ $9.24 | EDGAR |
| 2024-12-12 | 4 | Obenshain Andrew — President and CEO, Director | Sale (S): 971 @ $0.42 | EDGAR |
| 2024-12-12 | 4 | Colvin Richard A — Chief Medical Officer | Sale (S): 2,824 @ $0.42 | EDGAR |
| 2024-11-08 | 4 | Tita-Reid Najoh — Director | Grant/award (A): 24,900 @ $0 · Grant/award (A): 49,850 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Leschly Nick — Director | Grant/award (A): 24,900 @ $0 · Grant/award (A): 49,850 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Paulson Richard A. — Director | Grant/award (A): 24,900 @ $0 · Grant/award (A): 49,850 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Jones-Burton Charlotte — Director | Grant/award (A): 24,900 @ $0 · Grant/award (A): 49,850 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Agwunobi John O — Director | Grant/award (A): 24,900 @ $0 · Grant/award (A): 49,850 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Leiderman Elisabeth — Director | Grant/award (A): 24,900 @ $0 · Grant/award (A): 49,850 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Vachon Mark — Director | Grant/award (A): 24,900 @ $0 · Grant/award (A): 49,850 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | Colvin Richard A — Chief Medical Officer | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2024-10-02 | 4 | Vittiglio Joseph — Chief Business & Legal Officer | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2024-10-02 | 4 | Sterling O. James — Chief Financial Officer | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2024-10-02 | 4 | Cloonan Michael — Director | Grant/award (A): 37,350 @ $0 | EDGAR |
| 2024-10-02 | 4 | Klima Thomas J — See Remarks | Grant/award (A): 50,000 @ $0 · Sale (S): 1,006 @ $0.53 | EDGAR |
| 2024-10-02 | 4 | Obenshain Andrew — President and CEO, Director | Grant/award (A): 130,000 @ $0 · Sale (S): 34,780 @ $0.53 | EDGAR |
| 2024-07-03 | 4 | Sterling O. James — Chief Financial Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Cloonan Michael — Director | Grant/award (A): 74,775 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Klima Thomas J — See Remarks | Sale (S): 3,834 @ $0.97 | EDGAR |
| 2024-03-05 | 4 | Colvin Richard A — Chief Medical Officer | Sale (S): 6,770 @ $1.53 · Grant/award (A): 199,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Vittiglio Joseph — Chief Business & Legal Officer | Grant/award (A): 199,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Krawtschuk Christopher — Chief Financial Officer | Grant/award (A): 199,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Obenshain Andrew — President and CEO, Director | Sale (S): 6,095 @ $1.53 · Grant/award (A): 650,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Klima Thomas J — See Remarks | Sale (S): 4,573 @ $1.53 · Grant/award (A): 199,000 (derivative) @ $0 | EDGAR |
| 2024-02-06 | 4 | Klima Thomas J — See Remarks | Sale (S): 2,714 @ $0.90 | EDGAR |
| 2024-02-06 | 4 | Vittiglio Joseph — Chief Business & Legal Officer | Sale (S): 5,217 @ $0.90 | EDGAR |
| 2024-02-06 | 4 | Obenshain Andrew — President and CEO, Director | Sale (S): 1,879 @ $0.90 | EDGAR |
| 2024-01-09 | 4 | Obenshain Andrew — President and CEO, Director | Sale (S): 3,162 @ $1.43 | EDGAR |
| 2024-01-09 | 4 | Colvin Richard A — Chief Medical Officer | Sale (S): 597 @ $1.42 | EDGAR |
Recent 8-K events — bluebird bio, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-06-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-20 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2024-12-13 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2024-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2024-10-04 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BLUE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →